Clinical trial
Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)
NCT01257581 is registered in ClinicalTrials.gov with Nazem Atassi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Nazem Atassi
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2011
- Completion date
- February 28, 2013
- Enrollment
- 60 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.